Health and Healthcare
Short Interest Rises Across the Board in Major Biotechs
Published:
Last Updated:
The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected stocks for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise slightly to 10.63 million shares from the previous level of 10.41 million. Shares closed most recently at $147.11, in a 52-week trading range of $130.09 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 3.37 million from the previous level of 2.76 million. Shares closed Wednesday at $257.22, within a 52-week range of $242.07 to $480.18.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest jump to 39.79 million shares from 21.37 million in the previous period. Shares closed Wednesday at $89.36, in a 52-week trading range of $81.89 to $123.37.
MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 130.25 million shares. The previous reading was 124.41 million. Shares closed most recently at $1.00, in a 52-week trading range of $0.64 to $7.32.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased to 5.66 million, compared to the previous level of 5.47 million. Shares closed most recently at $141.97, in a 52-week range of $130.51 to $208.88.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.